搜索 临床试验

本研究的目的是评估两种不同剂量的onvansertib，以选择最有效的最低剂量, and to assess the safety, 功效, 药物动力学, 以及onvansertib联合FOLFIRI +贝伐单抗或FOLFOX +贝伐单抗在一线KRAS或nras突变的转移性结直肠癌(CRC)患者中的药理学.

Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors.

这项研究正在研究一种名为REGN7075的研究性药物，该药物可以单独使用，也可以与cemiplimab联合使用，无论是否使用化疗. The study is focused on patients with certain solid tumors that are in an advanced stage. 该研究的目的是观察REGN7075单独使用和与西米单抗联合使用(有或没有化疗)的安全性和耐受性。, 并找出REGN7075与西米单抗联合(有或没有化疗)时给予晚期实体瘤患者的最佳剂量. Another aim of the study is to see how effective REGN7075 by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients.

The study is also looking at:

• 单独服用REGN7075或与西米单抗联合使用化疗或不使用化疗时可能出现的副作用.
• How REGN7075 works in the body by itself and in combination with cemiplimab with or without chemotherapy.
• REGN7075在单独给药和与西米单抗联合化疗或不联合化疗时，血液中存在多少REGN7075.
• 看看REGN7075是否单独或与西米单抗联合化疗或不化疗通过控制肿瘤细胞的增殖来缩小肿瘤来治疗癌症.

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express MSLN and have lost HLA-A*02 expression.

The main questions this study aims to answer are:

第一阶段: What is the recommended dose of A2B694 that is safe for patients

Phase 2: Does the recommended dose of A2B694 kill the solid tumor cells and protect the patient's healthy cells

Participants will be required to perform study procedures and assessments, and will also receive the following study treatments:

Enrollment and Apheresis in BASECAMP-1 (NCT04981119)

Preconditioning Lymphodepletion (PCLD) Regimen

A2B694 Tmod CAR T cells at the assigned dose

这是一项剂量递增和剂量扩展的1/2a期试验，旨在评估DB-1311在晚期实体瘤患者中的安全性和耐受性.

This first-in-human (FIH) 剂量递增 and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

This first-in-human study will evaluate the safety, 耐受性, 药物动力学, and antitumor activity of TORL-4-500 in patients with advanced cancer

This study will test the safety of a drug called SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.

Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic).

This study will have three parts. Parts A and B of the study will find out how much SGN-EGFRd2 should be given to participants. C部分将使用在A部分和B部分中发现的剂量来确定SGN-EGFRd2的安全性以及它是否对治疗实体肿瘤癌症有效.

This is a 第一阶段/2, 多中心, 开放标签(除非在联合特异性模块中另有规定)DCC-3116与抗癌疗法联合的研究. 主方案中的模块根据DCC-3116与其他抗癌药物的不同组合来定义.

This first-in-human study will evaluate the safety, 耐受性, 药物动力学, and antitumor activity of TORL-3-600 in patients with advanced cancer

这项研究将测试一种名为SGN-BB228的药物在患有黑色素瘤和其他难以治疗或已经扩散到全身的实体瘤的参与者中的安全性. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.

This study will have 3 parts. Parts A and B of the study will find out how much SGN-BB228 should be given to participants. C部分将使用A部分和B部分的信息来确定SGN-BB228是否安全以及它是否有效治疗实体肿瘤癌症.

本研究的主要目的是评估HRO761的安全性和耐受性，并确定推荐剂量。, i.e., HRO761单独或联合替利单抗或伊立替康的最佳安全和有效剂量，可以给予患有称为MSIhi(微卫星不稳定性高)或dMMR(错配修复缺陷)的特定分子改变的癌症患者，这可能最有效地治疗这些特定的癌症类型，并了解HRO761治疗这些癌症的效果.

The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.

The main questions it aims to answer are:

• 评估CPO301增加剂量的安全性和耐受性，并确定研究第二部分(A部分)的使用剂量。
• 在A部分中确定的剂量下，评估CPO301在非小细胞肺癌和其他潜在肿瘤类型患者中的安全性和耐受性(B部分)。
• To evaluate how quickly CPO301 is metabolized by the body (药物动力学 or PK)
• To evaluate if antibodies to the study drug develop (immunogenicity)
• To evaluate preliminary 功效 to the drug
• To correlate preliminary 功效 with mutations in a biomarker called EGFR

Participants will:

• Provide written informed consent
• Undergo screening tests to ensure they are eligible for study treatment
• 参加所有要求的研究访问，每3周静脉注射一次CPO301，直到研究医生确定应该停止研究治疗, based on how well a participant is doing on treatment
• Be followed for progression every 3 months for up to 2 years

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression.

The main questions this study aims to answer are:

• 第一阶段: What is the maximum or recommended dose of A2B530 that is safe for patients
• Phase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the patient's healthy cells

Participants will be required to perform study procedures and assessments, and will also receive the following study treatments:

• Enrollment and Apheresis in BASECAMP-1 (NCT04981119)
• Preconditioning Lymphodepletion (PCLD) Regimen
• A2B530 Tmod CAR T cells at the assigned dose

This is a 多中心, 随机, 非盲, XL092 + atezolizumab与regorafenib在微卫星稳定/微卫星不稳定低(MSS/MSI-low)转移性结直肠癌(mCRC)患者中的对照3期试验, after or are intolerant to standard-of-care (SOC) therapy.

这是一项剂量递增和剂量扩展的1/2a期试验，旨在评估DB-1305/BNT325在晚期实体瘤患者中的安全性和耐受性.